TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Single Center Randomized Clinical Trial Comparing Weaning From Mechanical Ventilation With Computer-driven System vs Usual Care in Children
Brief Summary: The purpose of this study is to determine whether a computer-driven system (Smartcare/PS) decreases weaning duration from mechanical ventilation when compared to usual care in children.


Options:
A: Inclusion Criteria:

* Intubated or tracheotomised patients requiring mechanical ventilation at 9:00 am for longer than 9 hours (within this time period invasive and non-invasive ventilation is permitted)

Exclusion Criteria:

* Cerebral trauma / surgery
* Age \< 18 years
* Do-not-resuscitate-order
* Duration of mechanical ventilation \> 24 h
* Patient is currently participating in this trial (including 90 days follow-up period)
B: Inclusion Criteria:

* The attending physician thinks that the patient will be able to breathe spontaneously or the patients is already breathing spontaneously.
* No vasopressor or inotropic medication, unless the patient is receiving some digitalin or small doses of dopamine (\< 5 µg/kg/min)
* Slight or no endotracheal tube gas-leakage (\[Vti - Vte\]/Vti ≤ 20%)
* Mechanical ventilation with a plateau pressure ≤ 25 cmH2O over PEEP
* PEEP ≤ 8 cmH2O
* FiO2 ≤ 60% in order to obtain pulse oxymetry ≥ 95%
* PaCO2 \< 70 mmHg on the last blood gases
* Extubation not expected the day of inclusion

Exclusion Criteria:

* N/A
C: Inclusion Criteria:

* Acute onset shortness of breath(\<7 days)
* PaO2/FiO2 \< 200 mm Hg (regardless of PEEP)
* Bilateral infiltrates on frontal chest radiograph
* \<18 mm Hg when measured or no clinical evidence of left atrial hypertension

Exclusion Criteria:

* Age less than 12 years
* Patients having underlying chronic lung disease
* Contraindication to permissive hypercapnia (raised intracranial pressure, acute cerebrovascular disorders, acute or chronic myocardial ischemia, right ventricular failure, uncorrected severe metabolic acidosis, sickle cell anemia, tricyclic antidepressant overdose, pregnancy)
D: Criteria for consent (before surgical procedure):

* Elective cardiac surgery
* Age 18 to 90 years
* Absence of pregnancy
* Body Mass Index \< 40 kg/m²
* Creatinine \< 200micromol/L)
* Baseline PaCO2 \> 50 mmHg)

Exclusion Criteria:

* Unexpected surgical procedure
* Major complication during surgery
* Early extubation expected (\< 1 hour)
* Broncho-pleural fistula
* Study ventilator not available

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics
Brief Summary: The purpose of this study is to determine if antibiotics are required in the management of skin abscess following incision and drainage.


Options:
A: Inclusion Criteria:

* Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.

Exclusion Criteria:

* Prior treatment of current cSSSI with an antimicrobial.
* Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.
B: Inclusion Criteria:

* Inclusion criteria include all patients age 16 and older who present to the emergency department with a skin abscess that requires incision and drainage.

Exclusion Criteria:

* Exclusion criteria include patients with diabetes, HIV, cancer or other immunocompromised patients.
* Additionally, any patients who received antibiotics within one week of presentation or were hospitalized in previous month will be excluded to minimize potential confounding variables.
* Pregnant and breastfeeding patients will also be excluded due to possible safety concerns with antibiotic treatment.
* Patients with abscesses on face, perirectal, or perianal regions, abscesses with known tracks or fistulas to deeper structures, or abscesses requiring surgical drainage in an operating room are excluded.
* Patients with fever or evidence of systemic infection
* Finally, patients with sulfa allergy will be excluded.
C: Inclusion Criteria:

* non-toxic patients
* immunocompetent patients
* 3 months to 18 years old
* English-speaking patients
* skin abscesses
* not on antibiotics

Exclusion Criteria:

* toxic patients
* immunocompromising co-morbidities
* less than 3 months old or older than 18 years of age
* non-english speaking
* on antibiotics
D: Inclusion Criteria:

* All patients age 18-65 who present to the emergency department with a skin abscess that requires incision and drainage.

Exclusion Criteria:

* Patients with diabetes, HIV, cancer or other immunocompromised patients.
* Additionally, any patients who received antibiotics within one week of presentation or were hospitalized in previous month will be excluded to minimize potential confounding variables.
* Pregnant and breastfeeding patients will also be excluded due to possible safety concerns with antibiotic treatment.
* Patients with abscesses on head, face, perirectal, or periananal regions, abscesses with known tracks or fistulas to deeper structures, or abscesses requiring surgical drainage in an operating room are excluded.
* Finally, patients with sulfa allergy will be excluded.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Impact of Periodontal Therapy on Endothelial Function
Brief Summary: The purpose of this study is to determine the effect of periodontal therapy on endothelial function and other biomarkers of cardiovascular disease


Options:
A: Inclusion Criteria:

* 35 years and older
* coronary artery disease
* more than 10 teeth
* chronic periodontitis defined as 2 non-adjacent teeth with probing depth 5+mm and periodontal attachment loss 4+mm

Exclusion Criteria:

* use of antibiotics in the last 6 months
* periodontal therapy in the last 12 months
B: Inclusion Criteria:

* children at the age of 7 months and their families, recruited from the general population

Exclusion Criteria:

* severe sickness
C: Inclusion Criteria:

* patients admitted to our institution with a diagnosis of AMI (ST segment elevation\> 0.1mV)
* older than 30 years
* with more than 8 teeth in the mouth
* with advanced periodontal disease

Exclusion Criteria:

* acute or chronical infection
* impossibility of attending the following interviews and/or the periodontal treatment
* refusing to signing the consent form
* individuals with substance abuse
* anticonvulsants and immunosuppressant drugs users
* pregnant and \\ or lactating women.
D: Inclusion Criteria:

* Subjects must be 25 years of age or older
* Three or more periodontal pockets with a probing depth (PD) \> 5mm
* Have at least 20 natural teeth
* Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria:

* History of antibiotic use in the previous three months
* Pregnant or lactating females
* Treatment with antihypertensive, antilipemic, antiarrhythmic, and other cardiovascular drugs
* Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases
* Previous history of cardiovascular disease: Acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular block, peripheral vascular disease, cerebrovascular accident
* Patients who received periodontal treatment within the last 3 months
* Patients who require antibiotic prophylaxis before examination or treatment
* Patients with mental retardation and dementia

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Safety of Vitamin D Supplementation in the Elderly
Brief Summary: This study will evaluate the safety over 6 months of two different doses of vitamin D (cholecalciferol) in men and women age 65 and older. It will also evaluate if supplementation with vitamin D improves physical performance.


Options:
A: Inclusion Criteria:

* willingness to withhold supplement use for duration of study
* willingness to avoid sun exposure for duration of study

Exclusion Criteria:

* vitamin D supplement use
* conditions that affect vitamin D metabolism by the body
B: Inclusion Criteria:

* ambulatory

Exclusion Criteria:

* hypercalcemia
* hypercalciuria \> 4 mg/kg body weight/day
* primary, secondary, or tertiary hyperparathyroidism
* renal insufficiency (serum creatinine \> 2 mg/dL )
* history of nephrolithiasis
* treatment with vitamin D (ergocalciferol, cholecalciferol, calcitriol)
* treatment with anticonvulsants
* Paget's disease
* severe cardiac, pulmonary, hepatic, renal, or neurological disease
* life expectancy \< 1 year
* participation in another trial
C: Inclusion Criteria: healthy women ages 55 and older who were at least four years postmenopausal living independently in a nine-county rural area of Nebraska

-

Exclusion Criteria:

1) chronic kidney disease, 2) Paget's metabolic bone disease, and 3) history of cancer except for superficial basal or squamous cell carcinoma of the skin and

-
D: Inclusion Criteria:

* 18 years
* healthy

Exclusion Criteria:

* supplementation of vitamin d and calcium
* hypercalcemia
* hypercalciuria
* chronical illness (diabetes, kidney diseases, cardiovascular diseases)
* serum-creatinine above 115 mmol/l
* pregnancy or breastfeeding women

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.
Brief Summary: Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.


Options:
A: Inclusion Criteria:

* elective surgery
* HbA1c \>=8% within 3 months before surgery
* Age \> 18 years

Exclusion Criteria:

* undergoing same day surgery without post-operative admission
* HbA1c \< 8%
* individuals undergoing bariatric surgery
* individuals with metastatic cancer or short life expectancy
B: Inclusion Criteria:

* Patients with type 2 diabetes from participating practices across NHS Leicester, Warwickshire and Coventry.

Exclusion Criteria:

* Patients unable to give informed consent,
* Terminal cancer, OR
* Pregnant.
C: Inclusion Criteria:

* Provision of informed Consent
* Patients suffering from diabetes type II, insulin dependent or not insulin dependent.

Exclusion Criteria:

* Type I diabetes
* Pregnancy diabetes
* Hospitalisation, as this is a primary care study
* Patients who are member of the Belgian Diabetes Convention
D: Inclusion Criteria:

* all patients aged 40 or older with newly diagnosed diabetes between 1 March 1989 and 28 February 1991 based on hyperglycaemic symptoms or raised blood glucose values measured in general practice

Exclusion Criteria:

* threatening somatic disease, severe mental illness, or unwillingness to participate. For our analysis, we also excluded non-white patients and patients whose diagnosis was not established by a blood glucose measurement at a major laboratory within 500 days after diagnosis.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan: A Community-based Randomized Control Trial
Brief Summary: The investigators hypothesize that application of 4% Chlorhexidine to the cord stump and meticulous hand washing by primary health care providers of newborn infants will reduce the incidence of Omphalitis and thereby Neonatal Mortality as compared to standardized dry cord care.


Options:
A: Inclusion Criteria:

* All healthy newborns, born in the study setting will be systematically enrolled in the trial

Exclusion Criteria:

* Infants with congenital/birth defects
* Infants with any localized infection on the peri-umbilical region at the time of birth or application of any other material such as dung, etc before enrollment on the Cord.
B: Inclusion Criteria:

* Gravidas with living fetus delivering at home in the care of identified study birth attendant (community) or admitted to the identified hospital (Civil Hospital Karachi) for delivery

Exclusion Criteria:

* Contraindications to cervical exam (e.g., placenta previa)
* Active genital herpes or vulvovaginal ulceration
* Known or suspected allergy to chlorhexidine
* Fetus with face presentation
* Fetal death
* Unwilling/unable to give informed consent
* Less than 16 years of age
C: Inclusion Criteria:

* Uttar Pradesh
* Newborns at home

Exclusion Criteria:

* Hospitalized babies
D: Inclusion Criteria:

* All liveborn infants born in the study area

Exclusion Criteria:

* Newborn infants who died prior to study staff arriving to conduct the interventions

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan: A Community-based Randomized Control Trial
Brief Summary: The investigators hypothesize that application of 4% Chlorhexidine to the cord stump and meticulous hand washing by primary health care providers of newborn infants will reduce the incidence of Omphalitis and thereby Neonatal Mortality as compared to standardized dry cord care.


Options:
A: Inclusion Criteria:

* All healthy newborns, born in the study setting will be systematically enrolled in the trial

Exclusion Criteria:

* Infants with congenital/birth defects
* Infants with any localized infection on the peri-umbilical region at the time of birth or application of any other material such as dung, etc before enrollment on the Cord.
B: Inclusion Criteria:

* live-born infants delivered in one of three upazillas of Sylhet District (Zakiganj, Khanaighat, Beanibazar)
* married women of reproductive age within their individual target areas listed above

Exclusion Criteria:

* individuals outside of the target area in Sylhet(Zakiganj, Khanaighat, Beanibazar)
* infants not met at home by a project worker during the first seven days of life
C: Inclusion Criteria:

* Pregnant
* Plan to deliver at Chris Hani Baragwanath Hospital or one of its satellite clinics
* Plan to remain in Soweto for at least two months after delivery
* Are able to understand and give informed consent
* Are at least 15 years old at time of registration

Exclusion Criteria:

* Planned delivery by caesarean section
* Antenatal ultrasound revealing major fetal congenital anomalies
* Have known or suspected condition in which vaginal exams are contraindicated, e.g. placenta previa
* Have a history of allergic reaction to any topical antiseptic solution
* Present to labour ward with infant born before arrival
* Present to labour ward with significant vaginal bleeding during labour
* Present with known intrauterine fetal death prior to randomization
* Subject noted to be in full cervical dilatation or have baby's head on perineum
* Infant noted to be in face presentation on first vaginal examination
* Noted to have genital ulcers present on first vaginal examination
D: Inclusion Criteria:

* Gravidas with living fetus delivering at home in the care of identified study birth attendant (community) or admitted to the identified hospital (Civil Hospital Karachi) for delivery

Exclusion Criteria:

* Contraindications to cervical exam (e.g., placenta previa)
* Active genital herpes or vulvovaginal ulceration
* Known or suspected allergy to chlorhexidine
* Fetus with face presentation
* Fetal death
* Unwilling/unable to give informed consent
* Less than 16 years of age

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: School Nurse-Delivered Smoking Cessation Intervention
Brief Summary: The purpose of this study is to conduct a randomized controlled school-based trial to evaluate the effectiveness of a four-session school nurse-delivered smoking cessation intervention in increasing abstinence rates among high school students who smoke.


Options:
A: Inclusion Criteria:

* Aged 13 to 17, regardless of smoking status
* Scheduled for routine or acute care office visit
* Parental consent and youth assent

Exclusion Criteria:

* Unable to complete study requirements
B: Inclusion Criteria:

* enrolled in grades 9-12
* report smoking at least one puff of a cigarette in the past 30 days
* willingness to participate in a smoking cessation intervention study
* able to speak and read English
* able to complete the baseline questionnaire independently, indicating ability to complete study assessments and protocols
* intending to remain enrolled in the school for the remainder of the school year
* willing to provide contact information for the next 12 months

Exclusion Criteria:

* unwilling/unable to provide informed assent
* planning to move out of the area in the next 6 months
C: Inclusion Criteria:

* Healthy male and female adolescents (12 - 16 years inclusive) with a total body weight greater than 30 kg who currently smoke an average of at least 3 cigarettes per day.

Exclusion Criteria:

* Male and female subjects with a positive urine drug screen and female subjects with a positive pregnancy test.
D: Inclusion Criteria:

* Students from Germany aged 9 to 14 years at baseline attending grades six and seven of regular German secondary schools (such as grammar, general, intermediate or comprehensive school) are eligible.

Exclusion Criteria:

* Older or younger pupils or pupils from other school types or countries or schools who previously participated in an event where the Smokerface app was presented are not eligible.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Sentinel Surveillance of Acute Malnutrition in the Region of Maradi, Niger, Children Under 5: Impact of a Preventive Intervention
Brief Summary: Malnutrition is a critical public health problem in developing countries. Malnutrition may be linked to more than one half of the deaths in children under 5 years old. In July 2001, after an intervention related to a measles epidemic, Medecins sans Frontieres-France opened a nutritional program in Maradi, in the South of Niger. The introduction of ready to use therapeutic foods (RUTF), in particular Plumpy'Nut (Nutriset, France) allowed for the treatment of the majority of children at their homes using ambulatory treatment. Children with complicated cases were cared for in an inpatient center. With ambulatory treatment the number of children cared for in the MSF program reached close to 70000 in 2006.

This study aimed to assess the effect of a 3-month distribution of RUTF in the context of a preventative supplementary feeding program. The primary hypotheses were that short-term RUTF supplementation at the village-level would prevent declines in weight-for-height and reduce the incidence of wasting in children 6 to 60 mo of age over a period of 8 mo. Because RUTF may have additional health effects, the intervention effect on height-for-age, stunting, mortality and morbidity from malaria, diarrhea, and respiratory infection were also examined.


Options:
A: Inclusion Criteria:

* resident in selected villages
* height between 60 and 80 cm.

Exclusion Criteria:

* refusal to participate
B: Inclusion Criteria:

* Gestational age ≤ 20 weeks
* Planning to remain in the study area during pregnancy and the following three years (i.e., a permanent resident of the study area)

Exclusion Criteria:

* Pregnancy identified and registered in the CHDP program before the beginning of the enrollment.
C: Inclusion Criteria:

* 6 to 18 months; either sex, having no acute illness, and be on at least one semi-solid or solid food in a day.

Exclusion Criteria:

* loss of appetite,
* oral lesion,
* congenital anomaly/acquired disorder affecting growth,
* severe acute malnutrition (SAM) defined by:

  * MUAC \< 115 mm or
  * WL \< -3 Z score or
  * bipedal edema,
  * persistent diarrhea,
  * tuberculosis,
  * any other chronic illness.
D: Inclusion Criteria:

* All children resident in randomized villages 6-59 months

Exclusion Criteria:

* N/A

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Sentinel Surveillance of Acute Malnutrition in the Region of Maradi, Niger, Children Under 5: Impact of a Preventive Intervention
Brief Summary: Malnutrition is a critical public health problem in developing countries. Malnutrition may be linked to more than one half of the deaths in children under 5 years old. In July 2001, after an intervention related to a measles epidemic, Medecins sans Frontieres-France opened a nutritional program in Maradi, in the South of Niger. The introduction of ready to use therapeutic foods (RUTF), in particular Plumpy'Nut (Nutriset, France) allowed for the treatment of the majority of children at their homes using ambulatory treatment. Children with complicated cases were cared for in an inpatient center. With ambulatory treatment the number of children cared for in the MSF program reached close to 70000 in 2006.

This study aimed to assess the effect of a 3-month distribution of RUTF in the context of a preventative supplementary feeding program. The primary hypotheses were that short-term RUTF supplementation at the village-level would prevent declines in weight-for-height and reduce the incidence of wasting in children 6 to 60 mo of age over a period of 8 mo. Because RUTF may have additional health effects, the intervention effect on height-for-age, stunting, mortality and morbidity from malaria, diarrhea, and respiratory infection were also examined.


Options:
A: Inclusion Criteria:

* Infants 6 to 12 months old
* Lives in Fort San Michel

Exclusion Criteria:

* Moderately or severely malnourished
* Peanut allergy
B: Inclusion Criteria:

* All children resident in randomized villages 6-59 months

Exclusion Criteria:

* N/A
C: Inclusion Criteria:

* WH≥80% of median of NCHS reference without bilateral pitting oedema;
* Age ≥ 6 months and ≤36 months;
* Member of a household with a dependency ratio \>4;
* Not planning to leave the study zone for the coming 5 months;

Exclusion Criteria:

* Not showing appetite;
* Age \< 6 months or age \> 36 months
* Weight-for-Height Z-score \<-2 and/or the presence of bilateral pitting oedema in children 6-36 months;
* Member of a household with a dependency ration ≤ 4;
* Clinical complications
* Presence of chronic illness, cardiac disease, congenital abnormalities, cancer;
* Being allergic to one of the ingredients of the RUF.
D: Inclusion Criteria:

* signed informed consent from at least one guardian
* age 6.00 months to 14.99 months
* weight-for-age \<-2.0 Z scores
* availability during the period of the study.
* permanent resident Lungwena Health Centre catchment area

Exclusion Criteria:

* moderate or severe wasting (WHM\<80% of the reference median)
* history of peanut allergy
* history of any serious allergic reaction to any substance, requiring emergency medical care
* history of anaphylaxis
* severe illness warranting hospital referral
* concurrent participation in another clinical trial with intervention to the child

Answer: B